Authors
Latest:
Dr. Temel on Anorexia and Cachexia in NSCLCJennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.
Latest:
HR-Positive Advances Highlight the Good News in Breast CancerRecent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus.
Latest:
Dr Woyach on Responses to Pirtobrutinib in CLL/SLL With/Without Prior BCL2 Inhibitor ExposureJennifer A Woyach, MD, discusses the efficacy of pirtobrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who progressed on treatment with a covalent BTK inhibitor, including subgroups with or without previous exposure to a BCL2 inhibitor.
Latest:
Salvage Therapy and Emerging Agents in Colorectal CancerJennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.
Latest:
Oncology Fellow Focuses on Compassionate End-of-Life CareDue to the misconception surrounding "hospice," many patients with cancer use excess hospital care and intensive care services at the end of life.
Latest:
Dr. Shih on Treating Lobular vs Ductal Breast CancersJennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.
Latest:
Dr. Chang on Genomic Testing in Breast CancerJenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.
Latest:
Dr. Pincus on Classifying HER2+ Tumors in Breast CancerJenny Pincus, MD, assistant professor of pathology, Northwestern University, Feinberg School of Medicine, discusses the classification of HER2-positive tumors in patients with breast cancer.
Latest:
Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast CancerAbemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.
Latest:
Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple MyelomaThe FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.
Latest:
Dr. Houber on the De-Escalation of Treatments for Breast CancerJens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.
Latest:
Dr. Radich on the Impact of MRD on Survival Outcomes in AMLJerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.
Latest:
Dr Calais on Controversies in the Treatment of Patients With Prostate CancerJeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.
Latest:
Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCLJeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Dr. Segal on Next-Generation Sequencing for Lung CancerJeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.
Latest:
Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell LymphomasJeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.
Latest:
Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With CancerJerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.
Latest:
Next Steps for Immunoscore in OncologyJerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.
Latest:
The Role of Companion Diagnostic Testing in Payer Decision MakingCompanion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.
Latest:
Jerry Lanchbury, PhD, Describes Myriad's HRD TestJerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.
Latest:
Dr. Mitchell on Clinical Trials Exploring Medical Marijuana for Patients With CancerJerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.
Latest:
Challenges Facing the Future of CholangiocarcinomaJesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.
Latest:
Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLCJessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).
Latest:
A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS TestingThe overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.
Latest:
Zebrafish Are Making Waves as Cancer ModelsThe field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.
Latest:
Navigating the Job Search for Surgical Oncology FellowsAs the end of training approaches, the job hunt begins. Below are some tips to follow to make the job-hunting process easier.
Latest:
Impact of Risk Evaluation and Mitigation Strategies in OncologyThe management of risk in medicine is emerging as a priority topic for numerous stakeholders, including patients, providers (physicians, other prescribers, and pharmacists), specialty pharmacies, industry, and government organizations.
Latest:
How Biomarker Testing Could Continue to Evolve in NSCLCJessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Latest:
Dr. Frakes on Late Toxicities in HPV-Associated Oropharynx Squamous Cell CarcinomaJessica Frakes, MD, assistant member, Department of Radiation Oncology, Moffitt Cancer Center, discusses some of the late toxicities seen in patients with HPV-positive oropharynx squamous cell carcinoma.
